Top Skin diseases

Immune Mediated Therapy

Hair loss is a type of skin disease, and the common types of hair loss are mainly divided into androgenic alopecia, alopecia areata, psychogenic alopecia, genetic alopecia, etc. 95% of the hair loss belongs to androgenic alopecia.

 

The pathogenesis of this disease involves genetic factors, androgenic effects, and environmental factors such as mental stress and unhealthy lifestyle habits. Androgens play a decisive role in the pathogenesis of androgenic alopecia, particularly in the conversion of testosterone to dihydrotestosterone by 5 α - reductase. Dihydrotestosterone binds to androgen receptors, leading to hair follicle atrophy and hair loss.

 

Skin photoaging is the damage caused by prolonged exposure to sunlight on the skin, resulting from the combined effects of natural aging and ultraviolet radiation. Manifesting as rough, thickened, and dry exposed areas of the skin, sagging skin, deepening and thickening wrinkles, excessive pigmentation or capillary dilation in the local area. Photoaging is more common in the elderly, with males experiencing it more frequently than females. It is more likely to occur on the face, neck, chest, back, and upper limbs and forearms.

 

If you want to know more about kidney iga nephropathy treatment, please visit our website.

 

As one of biomedical companies, we will do our best to meet all the needs of customers.

 

Youngen, based in Beijing, is a biopharmaceutical limited pioneering the development of next-generation siRNA drugs to silence specific mRNAs and reduce the production of proteins that cause diseases.

 

Enjoyed this article? Stay informed by joining our newsletter!

Comments

You must be logged in to post a comment.

About Author

Youngen, based in Beijing, is a biotechnology company pioneering the development of next-generation siRNA drugs to silence specific mRNAs and reduce the production of proteins that cause disease. Youngen has been dedicating to bring RNAi therapeutics to a broad spectrum of difficult-to-treat diseases, both rare and general population impacting millions of people around the world. Leveraging these platform technologies, we built diversified product pipelines with globally competitive, first-in-class and best-in-class potential. We’re exploring many therapeutic areas to bring more treatment options to the patients with metabolic and cardiovascular diseases, immune-mediated diseases, and neurological disorders. https://www.youngenbiomed.com/